arrow
Y

Yinghong Wang

the university of texas m d anderson cancer center
H指数:50
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Refractory immune-related adverse events (irAes) associated with immune checkpoint inhibitor therapy: a multiorgan management review

免疫检查点抑制剂治疗相关的难治性免疫相关不良事件(irAes):多器官管理综述

2026-04-190
PRE
Chronic sequelae of immune-related adverse events

免疫相关不良事件的慢性后遗症

2026-03-040
PRE
Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy

超越质子泵抑制剂:评估癌症免疫疗法中免疫介导性胃肠炎的治疗策略

2025-12-110
PRE
Determinants of Treatment Refractoriness in Immune-Mediated Diarrhea and Colitis Following Immune Checkpoint Inhibitor Therapy

免疫检查点抑制剂治疗后免疫介导性腹泻和结肠炎的治疗抵抗决定因素

2025-10-010
PRE
Safety and Predictors of Recurrence in Immune Checkpoint Inhibitor Rechallenge Post-Immune-Mediated Diarrhea and Colitis

免疫检查点抑制剂再挑战治疗在免疫介导性腹泻和结肠炎后的安全性与复发预测因子

2025-10-010
PRE
Reduced Immunosuppression Requirements With GLP-1 Receptor Agonists Use in Patients Experiencing Immune-Mediated Diarrhea and Colitis

GLP-1受体激动剂使用可降低免疫介导性腹泻和结肠炎患者的免疫抑制需求

2025-10-010
PRE
Oral Immune-Related Adverse Events in Patients With and Without Inflammatory Bowel Disease Receiving Immune Checkpoint Inhibitor Therapy: A Retrospective Cohort Study

免疫检查点抑制剂治疗下,有和无炎症性肠病患者口腔免疫相关不良事件:一项回顾性队列研究

2025-10-010
PRE
Comparative Survival Outcomes and Cluster Effect of Immune-Mediated Colitis and Multisystem Immune-Related Adverse Events in Patients Receiving Immune-Checkpoint Inhibitors

免疫检查点抑制剂治疗患者的免疫介导性结肠炎与多系统免疫相关不良事件的比较生存结局及聚集效应

2025-10-010
PRE
Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis

免疫检查点抑制前的胃肠道感染会阻碍治疗效果并增加结肠炎的风险

2025-08-100
OA
The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor

二甲双胍使用、免疫介导性结肠炎与接受检查点抑制剂治疗患者的总生存期之间的关联

2025-05-010
PRE